Safety/Efficacy of Everolimus and Neoral® in Adult Cardiac Transplant Patients With Established Allograft Vasculopathy
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Everolimus is an immunosuppressive drug that is being studied for preventing acute rejection
that can happen after heart transplantation.
It is usually used in combination with other immunosuppressive drugs such as cyclosporine.
The purpose of this study is to evaluate the change in kidney function after beginning
everolimus, while determining the most effective Neoral® (cyclosporine) dose to take with
everolimus, in adult cardiac transplant patients who have had their transplanted heart for at
least 1 year and who have cardiac allograft vasculopathy.